NCT05764954Active, not recruitingPhase 1
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 22 Feb 2023
- Start date
- 4 Aug 2023
- Primary completion date
- Aug 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Lung cancer
- NCT number
- NCT05764954
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- From 4 Aug 2023 to the primary completion date, Aug 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving therapy for concurrent active malignancy
Other illness
- Patients with a history of cardiac arrhythmias and/or pacemaker use
Other
- Patients with lung nodules \<1cm
- Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
- Patients with lung nodules that are \<50% solid of any size
Who the study is looking for
- The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
- The participant is ≥22 years of age on the day of signing informed consent.
- The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
- The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
- The participant with multiple nodules has one nodule that meets the criteria.
- The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Consent Only) Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Suffolk - Commack (Consent Only) Coordinator of this site? Confirm its status | Commack | United States | Unknown status |
| Memorial Sloan Kettering Westchester (Consent only) Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Memorial Sloan Kettering Monmouth (Consent Only) Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen (Consent Only) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Nassau (Consent Only) Coordinator of this site? Confirm its status | Uniondale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.